To investigate vascular perfusion and foveal avascular zone area in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) after intravitreal aflibercept therapy in central retinal vein occlusion eyes and their association with best-corrected visual acuity.
Thirty-five subjects with central retinal vein occlusion and macular edema were evaluated. After macular edema resolution following intravitreal aflibercept, subjects underwent optical coherence tomography angiography to measure SCP and DCP perfusion and the foveal avascular zone within a 3 × 3-mm area. Correlations between best-corrected visual acuity and optical coherence tomography angiography measurements were examined.
After intravitreal aflibercept therapy, mean retinal vascular area was 3.41 ± 0.74 mm2 in the SCP and 3.25 ± 0.91 mm2 in the DCP. Foveal avascular zone area was 1.03 ± 1.04 mm2 in the SCP and 1.78 ± 1.73 mm2 in the DCP. Improved best-corrected visual acuity was significantly associated with better SCP and DCP perfusion (both P < 0.001) and with smaller SCP and DCP foveal avascular zone areas (both P < 0.001). Additionally, SCP and DCP perfusion were negatively correlated with macular edema before treatment (P < 0.05) and ischemia (determined via pretreatment fluorescein angiography, P < 0.05), and positively correlated with photoreceptor integrity (P < 0.001).
Patients with better retinal perfusion and less retinal ischemia are associated with better visual outcomes after aflibercept in eyes with central retinal vein occlusion.
Optical coherence tomography angiography was used to examine retinal perfusion status in eyes with central retinal vein occlusion. Both superficial and deep capillary plexus perfusion are crucial for favorable visual outcomes after intravitreal aflibercept therapy.
Department of Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan.
Reprint requests: Taku Wakabayashi, MD, PhD, Department of Ophthalmology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, E-7, Suita, Osaka 565-0871, Japan; e-mail: email@example.com
None of the authors have any financial/conflicting interests to disclose.